A Trial to Evaluate the Optimal Dose of MV-LASV

A Randomized, Placebo-controlled Trial to Evaluate the Optimal Dose of MV-LASV, a New Vaccine Against LASSA Virus Infection, Regarding Safety, Tolerability & Immunogenicity in Healthy Volunteers Consisting of an Unblinded Dose Escalation & an Observer-blinded Treatment Phase

Sponsors

Lead Sponsor: Themis Bioscience GmbH

Collaborator: Coalition for Epidemic Preparedness Innovations
Harmony Clinical Research
Assign Data Management and Biostatistics GmbH

Source Themis Bioscience GmbH
Brief Summary

This is a randomized, placebo-controlled, single-center, dose finding phase I trial in healthy adult volunteer participants consisting of two phases, an unblinded dose escalation and an observer-blinded treatment phase.

The aim is to investigate the safety, tolerability and immunogenicity of MV-LASV after administration of two different dose levels of MV-LASV. Placebo will be applied to blind the different Treatment schedules.

Detailed Description

This is a prospective, interventional, observer-blinded, randomized, phase I trial, comparing different dose levels of MV-LASV. As safety precaution, the study will begin with enrollment of two successive unblinded dose groups of sentinel participants randomized into groups of four in an open-label fashion (group A and B).

Thereafter, 52 participants will be enrolled in an observer-blinded, randomized manner into one of the three treatment groups (A, B or C). Placebo will be applied to blind the different Treatment schedules.

After the screening visit, participants will bei enrolled to one of three Treatment groups. Visits for immunogenicity sample collection and safety assessments will be performed for 56 days, and additionally subjects will for long-term follow-up up to 365 days.

The investigator and site personnel assessing Adverse Events (AEs), all participants, as well as the sponsor's representatives involved in the monitoring and conduct of the study will be unblinded to which vaccine was administered within the unblinded treatment phase. Only the site personnel performing randomization, reparation and administration of Investigational Medicinal Product (IMP) will be unblinded within the randomized observer-blinded treatment phase.

Overall Status Recruiting
Start Date September 23, 2019
Completion Date December 2020
Primary Completion Date April 2020
Phase Phase 1
Study Type Interventional
Primary Outcome
Measure Time Frame
Rate of solicited and unsolicited Adverse Events (AEs) 56 days
Secondary Outcome
Measure Time Frame
Rate of Serious Adverse Events (SAEs) 365 days
Cell-mediated immunity as confirmed by the presence of functional CD4+ and CD8+ T-cells 56 days
Measurement of anti-LASV antibodies determined by Enzyme-linked Immunosorbent Assay (ELISA) 56 days
Quantification of functional, neutralizing antibodies via Virus Neutralization Tests (VNT) 56 days
Rate of abnormal laboratory parameters 56 days
RT-qPCR Analysis of MV-LASV Viral Vector in Human Blood, Urine, and Saliva Samples 42 days
Enrollment 60
Condition
Intervention

Intervention Type: Biological

Intervention Name: MV-LASV

Description: The MV-LASV vaccine candidate is a recombinant live attenuated viral vectored vaccine, based on the backbone of the measles Schwarz virus strain for prophylaxis of Lassa infection and will be administered in two different dose levels by intra muscular (i.m.) injection.

Intervention Type: Other

Intervention Name: Placebo

Description: A sterile physiological saline solution will be used as placebo to ensure blinding of the treatment with low dose MV-LASV and placebo within treatment group A. Additionally, the Placebo will be used as a control arm to enable comparison of treatment reactions within treatment groups B and C.

Eligibility

Criteria:

Inclusion Criteria:

1. Signed informed consent obtained before any trial-related activities

2. Healthy men or women aged 18 to ≤ 55 years on the day of consenting

3. Ability to comprehend the full nature and purpose of the study, including possible risks and side effects; ability to cooperate with the investigator and to comply with the requirements of the entire study

4. All female participants of childbearing potential, defined as all woman physiologically capable of becoming pregnant, must have a negative pregnancy test at screening

5. Willingness not to become pregnant or to father a child during the study up to 182 days after the first vaccination by practicing reliable methods of contraception

6. Availability during the duration of the trial

Exclusion Criteria:

1. Participation in another investigational clinical study (including exposure to an IMP or device) within four weeks before the screening visit or planned concurrent participation in another clinical study before study completion

2. History of immunodeficiency, known HIV infection or current hepatitis B/C infection

3. History of drug addiction including alcohol dependence within the last two years

4. Inability or unwillingness to avoid intake of more than around 20g alcohol per day during 48 hours after each vaccination

5. Vaccination within four weeks prior to first vaccination or planning to receive any non-study vaccine within 182 days after the first vaccination

6. Prior receipt of any Lassa vaccine

7. Recent infection within one week prior to Screening visit

8. Blood donations including plasma donations, 90 days prior to Screening visit and anticipated blood, plasma, tissue, sperm or organ donation, throughout the study until end of treatment period

9. Clinically relevant history of renal, hepatic, gastrointestinal, cardiovascular, respiratory, skin, hematological, endocrine, inflammatory, autoimmune or neurological diseases or clinically relevant abnormal laboratory values, that in the opinion of the investigator may interfere with the aim of the study

10. History of neoplastic disease (excluding non-melanoma skin cancer that was successfully treated) within the past five years or a history of any hematological malignancy

11. Behavioral, cognitive, or psychiatric condition that in the opinion of the investigator affects the ability of the participant to understand and cooperate with the study protocol

12. History of severe adverse reactions to vaccine administration, including anaphylaxis and related symptoms, such as urticaria, respiratory difficulty, angioedema and abdominal pain to vaccines, or history of allergic reaction likely to be exacerbated by any component of the vaccine

13. History of or present hearing deficit

14. Present thrombocytopenia and/or history of thrombocytopenia and/or bleeding disorders.

15. History of anaphylaxis to drugs or other allergic reactions, which the investigator considers compromising the safety of the volunteer

16. Use of medication during two weeks before the first vaccination and throughout the study, which the investigator considers affecting the validity of the study, except hormonal contraception or hormonal replacement therapy in female participants (prior to taking any medication within 72 hours before study vaccination, the participant should consult the investigator)

17. Use of immunosuppressive drugs like corticosteroids (excluding topical preparations) within 30 days prior to the first vaccination or anticipated use before completion of day 182

18. Receipt of blood products or immunoglobulins within 120 days prior to the Screening Visit or anticipated receipt of any blood product or immunoglobulin before completion of day 182

19. Pregnancy or lactation at screening or planning to become pregnant before completion of day 182

20. Unreliable contraception Methods

21. Persons in a direct relationship with the sponsor, an investigator or other study team members. Direct dependent relationships include close relatives (i.e. children, parents, partner/spouse, siblings) as well as employees of the clinical study site or the sponsor

22. Individuals who are living and/or working with severely immunocompromised people, children under 15 months old or pregnant women

23. Participants who travelled within one year prior to the first vaccination or plan to travel during the study to an endemic country

24. A rash, dermatological condition or tattoos that would, in the opinion of the Investigator, interfere with injection site reaction rating

Gender: All

Minimum Age: 18 Years

Maximum Age: 55 Years

Healthy Volunteers: Accepts Healthy Volunteers

Overall Official
Last Name Role Affiliation
Pierre Van Damme, MD Principal Investigator University of Antwerpen, Centre for the Evaluation of Vaccination (CEV)
Overall Contact

Last Name: Yvonne Tomberger, Mag

Phone: +4312367151

Email: [email protected]

Location
Facility: Status: Contact: Investigator: University of Antwerpen, Centre for the Evaluation of Vaccination (CEV) Pierre Van Damme Pierre Van Damme Principal Investigator
Location Countries

Belgium

Verification Date

October 2019

Responsible Party

Type: Sponsor

Keywords
Has Expanded Access No
Condition Browse
Number Of Arms 3
Arm Group

Label: MV-LASV low dose: treatment group A

Type: Experimental

Description: In total 24 participants will receive two low dose treatments with MV-LASV on day 0 and 28.

Label: MV-LASV high dose: treatment group B

Type: Experimental

Description: In total 24 participants will receive two high dose treatments with MV-LASV on day 0 and 28.

Label: Placebo: treatment group C

Type: Placebo Comparator

Description: In total 12 participants will receive placebo treatment on day 0 and 28.

Patient Data No
Study Design Info

Allocation: Randomized

Intervention Model: Parallel Assignment

Primary Purpose: Treatment

Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

Masking Description: As safety precaution, the study will begin with enrollment of two successive unblinded dose groups of sentinel participants randomized into groups of four in an open-label fashion (group A and B). All site personnel, Sponsor and participants will be unblinded. Then remaining participants will be randomized in a blinded manner to one of three Treatment Groups (A, B, C). Site personnel responsible for study medication handling, preparation and Administration will be unblinded, only.

Source: ClinicalTrials.gov